Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

NCT02129322 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped patients not enrolled

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib
DRUG: S-1
DRUG: Oxaliplatin

Sponsor

Zhejiang University